Item 7.01. Regulation FD Disclosure.
The Securities and Exchange Commission (the "SEC") has issued an Order under
Section 36 of the Securities Exchange Act of 1934, Modifying Exemptions From the
Reporting and Proxy Delivery Requirements for Public Companies, dated March 25,
2020 (Release No. 34-88465) (the "Order"), which provides conditional relief to
public companies that are unable to timely comply with their filing obligations
as a result of the novel coronavirus ("COVID-19") pandemic. Due to COVID-19,
Enzo Biochem, Inc. (the "Company," "we," "us," or "our") is filing this Current
Report on Form 8-K to report that it is postponing the filing date of its Enzo
Biochem Inc. Salary Reduction Profit Sharing Plan (the "Plan) on Form 11-K for
the year ended December 31, 2019 (the "Form 11-K") in reliance on the Order. We
estimate that we will file our Form 11-K on or about July 31, 2020 but in any
event no later than 45 days after June 28, 2020.
Due to the government imposed restrictions within the New York City region where
our corporate offices are situated, COVID-19 has limited the physical access of
our personnel working remotely to corporate files related to the Plan. This in
turn has caused and will continue to cause delays in the preparation, review and
audit process relating to the Form 11-K. Accordingly, we are relying on the
Order to postpone the filing of our Form 11-K to provide us with additional time
to develop and process our financial information as well as prepare additional
disclosure potentially required as it relates to COVID-19.
The information discussed under Item 7.01 above shall not be deemed "filed" for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or
incorporated by reference in any filing by the Company under the Securities Act
of 1933, as amended, except as shall be expressly set forth by specific
reference in such a filing.
1© Edgar Online, source Glimpses
ENZO BIOCHEM, INC. 
